论文部分内容阅读
【目的】探讨阿嗪米特联合胃肠动力药物莫沙必利对胆汁反流性胃炎患者的治疗效果。【方法】选择本院于2011年12月至2013年12月接诊的120例胆汁反流性胃炎患者的临床病例资料，将所有接诊患者按随机数字表分为对照组60例患者，采用碳酸铝镁联合莫沙必利治疗，观察组60例患者，采用阿嗪米特联合莫沙必利治疗，比较两组患者的治疗效果。【结果】治疗后，观察组患者的总有效率为86．67％，明显高于对照组患者66．67％，组间差异具有统计学意义（ P ＜0．05）；观察组患者的症状评分均较对照组患者治疗前明显改善，组间差异均具有明显统计学意义（ P ＜0．05）；观察组患者的胆汁反流次数和最长反流时间等均明显低于对照组患者，组间差异具有明显统计学意义（ P ＜0．05）。【结论】阿嗪米特与胃肠动力药物莫沙必利联合应用，可通过协同治疗作用，不但促进胆汁规律性地分泌，而且增加胃肠运动，促进食物消化能力，改善患者的临床不适症状，有利于患者病情改善和生活质量的提高，值得临床推广应用。“,”To explore the clinical efficacy of azintamide combined with gastrointestinal motili-ty drug mosapride for the treatment of bile reflux gastritis .[Methods]Totally 120 patients with bile reflux gastritis in our hospital from Dec .2011 to Dec .2013 were selected and randomly divided into control group ( n=60) treated with aluminum magnesium carbonate and mosapride and the observation group ( n=60) treated with azintamide and mosapride .Clinical efficacy was compared between two groups .[Results] After treat-ment ,the total effective rate in observation group was 86 .67% ,which was significantly higher than that in control group ,and there was significant difference between two groups ( P < 0 .05) .Compared with control group ,the symptom scores in observation group were obviously improved ,and there was significant difference between two groups( P < 0 .05) .The frequency of bile reflux and most general reflux time in observation group were obviously lower than those in control group ,and there was significant difference ( P < 0 .05) .[Conclusion] Azintamide combined with gastrointestinal motility drug mosapride can not only promote regular bile secretion ,but also increase gastrointestinal motility and food digest ability ,improve clinical uncomfortable symptoms and is helpful for the improvement of pathogenetic condition and quality of life through the synergis-tic effect .Therefore ,it is worthy of clinical application .